0001193125-17-128832.txt : 20170419 0001193125-17-128832.hdr.sgml : 20170419 20170419163202 ACCESSION NUMBER: 0001193125-17-128832 CONFORMED SUBMISSION TYPE: DFAN14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170419 DATE AS OF CHANGE: 20170419 EFFECTIVENESS DATE: 20170419 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PROVECTUS BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000315545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900031917 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DFAN14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36457 FILM NUMBER: 17770344 BUSINESS ADDRESS: STREET 1: 7327 OAK RIDGE HWY STREET 2: SUITE B CITY: KNOXVILLE STATE: TN ZIP: 37931 BUSINESS PHONE: 865-769-4011 MAIL ADDRESS: STREET 1: 7327 OAK RIDGE HWY STREET 2: SUITE B CITY: KNOXVILLE STATE: TN ZIP: 37931 FORMER COMPANY: FORMER CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020417 FORMER COMPANY: FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC DATE OF NAME CHANGE: 20011126 FORMER COMPANY: FORMER CONFORMED NAME: SPM GROUP INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CULPEPPER PETER R CENTRAL INDEX KEY: 0001281041 FILING VALUES: FORM TYPE: DFAN14A MAIL ADDRESS: STREET 1: 7327 OAK RIDGE HWY STREET 2: SUITE A CITY: OAK RIGE STATE: TN ZIP: 37931 DFAN14A 1 d376998ddfan14a.htm DFAN14A DFAN14A

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934

 

 

Filed by the registrant  ☐                              Filed by a party other than the registrant  ☒

Check the appropriate box:

 

☐   Preliminary proxy statement
☐   Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2))
☐   Definitive proxy statement
☐   Definitive additional materials
☒   Soliciting material pursuant to §240.14a-12

Provectus Biopharmaceuticals, Inc.

(Name of Registrant as Specified In Its Charter)

Peter R. Culpepper

(Name of Person Filing Proxy Statement)

Payment of filing fee (Check the appropriate box):

☒   No fee required.
☐   Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
  (1)  

Title of each class of securities to which transaction applies:

 

     

  (2)  

Aggregate number of securities to which transactions applies:

 

     

  (3)  

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11:

 

     

  (4)  

Proposed maximum aggregate value of transaction:

 

     

  (5)  

Total fee paid:

 

     

☐   Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
  (1)  

Amount previously paid:

 

     

  (2)  

Form, schedule or registration statement no.:

 

     

  (3)  

Filing party:

 

     

  (4)  

Date filed:

 

     

 

 

 

April 19, 2017

Dr. Timothy Scott

President

Provectus Biopharmaceuticals, Inc.

7327 Oak Ridge Highway

Knoxville, TN 37931

Dear Dr. Scott:

This is to inform you that I will not be nominating persons for election at the 2017 annual meeting of stockholders of Provectus Biopharmaceuticals, Inc., to serve as directors of Provectus.

Sincerely,

/s/ Peter R. Culpepper

Peter R. Culpepper

 

2